Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Type I Cryoglobulinemia (ICE Study)
2021-001992-17Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in cryoglobulinaemia, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete clinical response rate of cryoglobulinemia vasculitis symptoms at week 20. Started Jun 2021; status: active.
02
Drugs
isatuximab
03
Conditions
cryoglobulinaemia
Beyond the preview
Go deeper on 2021-001992-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001992-17.